Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Inventage Lab Inc. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 6 distinct art units, indicating a broad technical focus within its primary sector. The prosecution work involves 7 distinct examiners, showing that each pending office action is currently being handled by a different individual at the patent office.
AL-AWADI, DANAH J is identified as the busiest examiner for this portfolio, though they are responsible for only 1 busiest examiner pending action. This suggests a decentralized prosecution environment where no single examiner holds a significant portion of the active workload. Practitioners should prepare for varied examination styles given that the 7 pending office actions are not concentrated under any specific individual.
The presence of 7 pending office actions across 6 distinct art units suggests that while the company operates in Biotechnology & Pharmaceuticals, its intellectual property touches upon several specialized sub-disciplines. Navigating 7 distinct examiners requires a flexible strategy to address the individual preferences of each examiner. This lack of concentration is further evidenced by the fact that the busiest examiner, AL-AWADI, DANAH J, only manages 1 busiest examiner pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AL-AWADI, DANAH J | 1 | 54.6% | +13.2% |
| SCHLIENTZ, NATHAN W | 1 | 41.3% | -18.8% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| BHATIA, ANSHU | 1 | 84.2% | +17.1% |
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | — |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17762701 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | ATKINSON, JOSHUA ALEXANDER | 6d |
| 18281915 | LIPID NANOPARTICLE PREPARATION METHOD AND PREPARATION APPARATUS THEREFOR | SHOMER, ISAAC | 71d |
| 18856012 | METHOD FOR PREPARING MICROPARTICLES CONTAINING MOXIDECTIN AND SUSTAINED RELEASE INJECTABLE COMPOSITION COMPRISING MICROPARTICLES PREPARED BY SAME PREPARATION METHOD | AL-AWADI, DANAH J | — |
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | — |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | — |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| 1615 | 1 |
| 1616 | 1 |
| 1626 | 1 |
| 1774 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856012 | METHOD FOR PREPARING MICROPARTICLES CONTAINING MOXIDECTIN AND SUSTAINED RELEASE INJECTABLE COMPOSITION COMPRISING MICROPARTICLES PREPARED BY SAME PREPARATION METHOD | AL-AWADI, DANAH J | 1615 | §103DP | Non-Final OA | — | Pending | Mar 24, 2025 |
| 18992017 | SUSTAINED-RELEASE INJECTABLE COMPOSITION CONTAINING DUTASTERIDE | SCHLIENTZ, NATHAN W | 1616 | §103DP | Non-Final OA | — | Pending | Jan 07, 2025 |
| 18976930 | NOVEL LONG-ACTING INJECTABLE COMPOSITION FOR PREVENTING OR TREATING ANDROGENETIC ALOPECIA CONTAINING FINASTERIDE | KUCKLA, ANNA GRACE | 1626 | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18291366 | NANO LIPID PARTICLES MANUFACTURING CHIP, NANO LIPID PARTICLES MANUFACTURING SYSTEM HAVING THE SAME, AND NANO LIPID PARTICLES MANUFACTURING METHOD | BHATIA, ANSHU | 1774 | §102§103§112 | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18281915 | LIPID NANOPARTICLE PREPARATION METHOD AND PREPARATION APPARATUS THEREFOR | SHOMER, ISAAC | 1612 | §103 | Final Rejection | 71d | Pending | Sep 13, 2023 |
| 17762701 | SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG | ATKINSON, JOSHUA ALEXANDER | 1612 | §103Other | Non-Final OA | 6d | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInventage Lab Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Danah J Al-Awadi has the most, with 1 of Inventage Lab Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
